Neil Almstead, serving as the Chief Technical Operations Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), executed a series of transactions on July 9, 2026, involving the sale of 2,464 shares of the company's common stock. The total value realized from these sales was $222,376. The shares were divested at a weighted average price of $90.25, with individual transaction prices ranging between $90.00 and $90.70 per share.
These sales followed the acquisition of an equal number of common shares on the same date. Mr. Almstead acquired the 2,464 shares by exercising stock options at a price of $46.54 per share, resulting in a total exercise cost of $114,674. Both the option exercise and the subsequent sale were conducted pursuant to a Rule 10b5-1 plan, which was adopted by Mr. Almstead on November 11, 2025.
The timing of the sale is notable, as PTC Therapeutics shares have delivered a 75% return over the past year and were trading near their 52-week high of $90.87 when the transaction occurred. Following these transactions, Mr. Almstead directly holds 60,299 shares of PTC Therapeutics common stock. Additionally, his spouse indirectly holds 2,899 shares.
According to InvestingPro analysis, the stock currently appears slightly overvalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive Pro Research Reports covering PTCT and 1,400+ other US equities.
The exercised stock option was granted on January 3, 2025, with an exercise price of $46.54 and an expiration date of January 2, 2035. The option vests over four years, with 25% of the shares vesting on January 3, 2026, and an additional 6.25% vesting at the end of each successive three-month period thereafter, starting April 3, 2026. After the exercise, Mr. Almstead holds 45,036 unexercised stock options.
PTC Therapeutics IncFollowAnalyze PTCTIncluded in our AI-picked strategies·Review strategies81.33▼-3.52(-4.15%)Closed81.50▲+0.17(+0.21%)After Hours·17:17:221D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:00808182Analyze PTCTIn other recent news, PTC Therapeutics reported strong financial results for the first quarter of 2026, surpassing analyst expectations. The company posted an earnings per share (EPS) of -$0.03, significantly better than the forecasted -$0.46. Revenue for the quarter came in at $273 million, exceeding the anticipated $224.08 million. In addition to these earnings highlights, PTC Therapeutics has been the subject of several analyst upgrades due to the promising outlook of Sephience. Jefferies upgraded the stock to Buy, raising the price target to $85, citing Sephience's potential to exceed revenue expectations. Similarly, TD Cowen upgraded the stock to Buy, increasing the price target to $90 and noting the company's operational improvements and successful product launch. BofA Securities reiterated its Buy rating, maintaining a $93 price target, and expressed confidence in Sephience achieving over $2 billion in global peak sales. These developments highlight the growing confidence in PTC Therapeutics' future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Is PTCT undervalued—or a trap?Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what PTCT is really worth.Get instant clarity on PTCT—plus thousands of other stocks—before the opportunity disappears.July Sale - 60% Off InvestingPro